India's Shasun Pharmaceuticals has entered into a collaboration with Nanoparticle Biochem, Inc. (NBI) to develop a nanoparticle radioactive medicine NBI-29 to treat prostate cancer.

OGX-011, an experimental anti-clusterin agent, could almost double the life expectancy of patients with advanced prostate cancer, says a Canadian study.

India's biotechnology sector is expected to touch as much as $8 billion growing at a pace of 20% per annum for the next five years, says a recent survey report  titled 'India Life Sciences: Vision 2015' prepared by the Confederation of Indian Industries (CII) and Yes Bank Knowledge Report .